United States Australia Brazil Canada Germany India Ireland Japan Mexico New Zealand Philippines South Africa United Kingdom
The GMP Insider podcast artwork
Science

The GMP Insider

by Tushar Arora
生命科学ポッドキャスト科学
Share this ranking Is this your show? Claim it
Listen on Apple PodcastsRSS feed

Chart positions today · United States

Not on the United States charts we track today.

If you like The GMP Insider, try…

Latest episodes

  • How to Respond to an FDA 483 (and Warning Letter) in 15 Working Days

    October 28, 2026 · 15 min

    The inspection is over — and the second half of it has just started. Your written response to a Form FDA 483 is due within 15 working days, and FDA weighs it before deciding whether the matter ends there or escalates to a Warning Letter…

  • FDA Inspection Readiness 2026: The New Cross-System Inspection Model

    October 26, 2026 · 15 min

    FDA doesn't inspect your quality systems in silos anymore. The new inspection model is hypothesis-driven: the investigator pulls one thread — a complaint, a repeat deviation — through CAPA, risk management, and design as a single connected…

  • Why FDA Rejects Your CAPA: 5 CAPA Effectiveness Failures Explained

    October 21, 2026 · 14 min

    Nearly nine out of ten human-drug warning letters include at least one inadequate CAPA response. Your corrective action plan is the single most rejected document in FDA enforcement — and it's not for lack of effort. Marcus and Priya count…

  • Why FDA Rejects Your CAPA: 5 CAPA Effectiveness Failures Explained

    October 21, 2026 · 14 min

    Nearly nine out of ten human-drug warning letters include at least one inadequate CAPA response. Your corrective action plan is the single most rejected document in FDA enforcement — and it's not for lack of effort. Marcus and Priya count…

  • OOS Investigation Explained: Phase 1 vs Phase 2 (21 CFR 211.192)

    October 19, 2026 · 15 min

    An out-of-specification result lands on your desk — and one wrong decision in the next hour can manufacture the evidence for your own warning letter. Marcus and Priya break down the two-phase OOS investigation step by step: Phase 1, the…

Show 7 more episodesShow fewer episodes

  • ALCOA+ Explained: The 9 Data Integrity Principles FDA Actually Cites

    October 14, 2026 · 15 min

    When an FDA investigator stops trusting your data, the inspection is over — because if the records can't be trusted, nothing built on them can be. Marcus and Priya break down all nine ALCOA+ principles — Attributable, Legible…

  • Top 10 FDA 483 Observations in 2026 (and How to Avoid Each One)

    October 12, 2026 · 13 min

    Every year, FDA investigators write thousands of 483 observations — and almost every one was avoidable. Marcus and Priya count down the ten most-cited observations in drug manufacturing for 2026, what investigators are actually finding…

  • Quality Debt: The Hidden Liability Inside Pharmaceutical Quality Systems

    October 7, 2026 · 7 min

    Every shortcut, deferred CAPA, and "we'll fix it later" is a loan — and quality debt charges interest. Repeat deviations, findings, and warning letters are just the payments coming due. • What quality debt is and how it silently…

  • The Hidden Cost of Poor Quality: The Business Impact Beyond Recalls

    October 5, 2026 · 16 min

    Recalls make the headlines. But the real cost of poor quality never makes the press release — it hides in rework, investigations, remediation, and the launches that never happen. • The costs nobody puts on the recall announcement •…

  • Why CAPA Doesn't Fix Culture: Symptoms vs Systems

    September 30, 2026 · 11 min

    Your CAPA system can be perfect on paper and still change nothing — because CAPAs fix symptoms, and culture is the system underneath. • Why brilliant CAPAs die in broken cultures • Symptoms vs systems: knowing which one you're treating •…

  • Compliance vs Effectiveness: Is Your Quality System Healthy?

    September 28, 2026 · 11 min

    Compliant doesn't mean effective. Effective doesn't mean sustainable. Most quality systems are only one of the three — and leadership can't tell which. • The three lenses every quality system needs • Why compliance alone is a fragile…

  • When a Green Dashboard Lies: Signals Your Metrics Miss

    September 23, 2026 · 8 min

    Every metric green, every trend flat — and the system is rotting underneath. Dashboards don't lie on purpose. They lie by design. • Why green metrics create dangerous comfort • The quality signals dashboards systematically miss • What to…

Full episode archive on Apple Podcasts →

About the show

GMP Insider is your go-to podcast for practical insights into pharmaceutical quality, Good Manufacturing Practices (GMP), and regulatory compliance. Designed for quality professionals, manufacturing teams, and pharma leaders, this show breaks down complex regulations into clear, real-world guidance. Each episode explores topics like audits, CAPA, data integrity, quality systems, validation, and global regulatory expectations — all with a focus on protecting patients and building strong quality cultures. Whether you work in Quality Assurance, Quality Control, Manufacturing, or Regulatory Affairs, GMP Insider helps you stay compliant, confident, and ahead in an ever-evolving pharmaceutical industry. New episodes deliver:• GMP best practices• Audit readiness strategies• Real compliance case studies• Industry trends and updates• Expert tips from quality professionals From batch to patient — quality is everything.